TY - JOUR
T1 - Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals
AU - Taramasso, L.
AU - Madeddu, G.
AU - Ricci, E.
AU - De Socio, G. V.
AU - Menzaghi, B.
AU - Orofino, G.
AU - Passerini, S.
AU - Franzetti, M.
AU - Maggi, P.
AU - Dentone, C.
AU - Martinelli, C.
AU - Celesia, B. M.
AU - Penco, G.
AU - Libertone, R.
AU - Quirino, T.
AU - Bonfanti, P.
AU - Di Biagio, A.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - The relationship between hepatic tolerance and hepatitis C virus (HCV) co-infection has not been extensively studied in clinical practice. We assessed the efficacy and safety of raltegravir-based therapy in an Italian cohort of HIV/HCV co-infected patients. One hundred and forty patients with HIV/HCV co-infection initiating raltegravir from SCOLTA project (Surveillance Cohort Long-Term Toxicity Antiretrovirals) were examined. Of them, 43 were women, with mean age of 45.4. ±. 6.4. years; 65 (46%) had undetectable HIV-RNA. <50. copies/mL and 75 (54%) HIV-RNA. ≥. 50. copies/mL. According to CDC classification, 49 (35%) were in stage C. Based on Fib4 score at the time of starting raltegravir, patients were classified in class I in 41 cases, class II in 68 and in class III in 31 cases. Globally, the Fib4 score slightly decreased during 24. months follow-up, from 2.2 to a value of 1.8. Hepatic adverse events of any grade were observed in 67 patients, of which only 2 cases (3%) had severe liver toxicity (grade 3-4). Only one patient had to discontinue the therapy because of adverse events. According to univariate analysis, being in CDC stage C represented a risk for the development of liver toxicity, with a hazard ratio (HR) of 2.27 (95% CI 1.06-4.84, P= 0.033). None of the other variables considered (age, sex, years since detection of HIV and HCV-RNA detectable, years of previous HIV therapy, concomitant therapy with PI or NRTI, CD4+ cell count, Fib4, and transaminases level at baseline) resulted statistically correlated to the outcome. In conclusion, raltegravir-based regimens can be safely used in HCV infected patients; in this study, the hepatic toxicity has been found to be more frequent in patients with an advanced HIV disease (CDC stage C), independently of HIV-RNA suppression at raltegravir initiation.
AB - The relationship between hepatic tolerance and hepatitis C virus (HCV) co-infection has not been extensively studied in clinical practice. We assessed the efficacy and safety of raltegravir-based therapy in an Italian cohort of HIV/HCV co-infected patients. One hundred and forty patients with HIV/HCV co-infection initiating raltegravir from SCOLTA project (Surveillance Cohort Long-Term Toxicity Antiretrovirals) were examined. Of them, 43 were women, with mean age of 45.4. ±. 6.4. years; 65 (46%) had undetectable HIV-RNA. <50. copies/mL and 75 (54%) HIV-RNA. ≥. 50. copies/mL. According to CDC classification, 49 (35%) were in stage C. Based on Fib4 score at the time of starting raltegravir, patients were classified in class I in 41 cases, class II in 68 and in class III in 31 cases. Globally, the Fib4 score slightly decreased during 24. months follow-up, from 2.2 to a value of 1.8. Hepatic adverse events of any grade were observed in 67 patients, of which only 2 cases (3%) had severe liver toxicity (grade 3-4). Only one patient had to discontinue the therapy because of adverse events. According to univariate analysis, being in CDC stage C represented a risk for the development of liver toxicity, with a hazard ratio (HR) of 2.27 (95% CI 1.06-4.84, P= 0.033). None of the other variables considered (age, sex, years since detection of HIV and HCV-RNA detectable, years of previous HIV therapy, concomitant therapy with PI or NRTI, CD4+ cell count, Fib4, and transaminases level at baseline) resulted statistically correlated to the outcome. In conclusion, raltegravir-based regimens can be safely used in HCV infected patients; in this study, the hepatic toxicity has been found to be more frequent in patients with an advanced HIV disease (CDC stage C), independently of HIV-RNA suppression at raltegravir initiation.
KW - Efficacy
KW - HCV
KW - Hepatitis
KW - Raltegravir
KW - Safety
KW - Tolerability
UR - http://www.scopus.com/inward/record.url?scp=84922232329&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922232329&partnerID=8YFLogxK
U2 - 10.1016/j.biopha.2014.12.006
DO - 10.1016/j.biopha.2014.12.006
M3 - Article
C2 - 25661363
AN - SCOPUS:84922232329
VL - 69
SP - 233
EP - 236
JO - Biomedicine and Pharmacotherapy
JF - Biomedicine and Pharmacotherapy
SN - 0753-3322
ER -